ClinConnect ClinConnect Logo
Search / Trial NCT05759013

Pivotal Evaluation of Abdominal Neuromuscular Electrical Stimulation (VentFree) for Weaning From Mechanical Ventilation

Launched by LIBERATE MEDICAL · Feb 24, 2023

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Respiratory Muscle Stimulation Mechanical Ventilation

ClinConnect Summary

Approximately 40% of patients who receive invasive ventilation require more than four days of ventilator support. Every additional day of mechanical ventilation results in increased patient morbidity and mortality and increased economic cost. Mechanically ventilated patients often develop expiratory muscle weakness, which has been linked to failed extubation and weaning.

Neuromuscular electrical stimulation (NMES) uses electrical pulses to induce a muscle contraction and has been shown to reduce or retard muscle atrophy. NMES applied to the abdominal wall muscles has been shown to improve ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Participant is ≥ 22 years of age.
  • 2. Participant has been receiving invasive mechanical ventilation for ≥ 24 hours.
  • Exclusion Criteria:
  • 1. Participant has been receiving invasive mechanical ventilation for \> 96 hours.
  • 2. Participant is scheduled or expected to be disconnected from mechanical ventilation ≤ 24 hours after enrollment.
  • 3. Participant was intubated for ≥ 24 hours during a prior episode of invasive mechanical ventilation during current hospitalization.
  • 4. Participant has a BMI ≥ 40 Kg/m2.
  • 5. Participant has no contraction of the abdominal wall muscles in response to abdominal FES as determined by ultrasound.
  • 6. Participant has a pre-existing neuromuscular or muscular disorder that could affect the respiratory muscles (e.g., spinal cord injury or Guillain-Barré syndrome).
  • 7. Participant has had open abdominal surgery ≤ 4 weeks prior to enrollment.
  • 8. Participant has open or damaged skin at area of electrode placements.
  • 9. Participant has a pacemaker and/or implanted electronic device.
  • 10. Participant is known or expected to be pregnant. NOTE: A negative urine or blood pregnancy test will be documented during screening for women of child-bearing potential.
  • 11. Participant is actively pharmacologically paralyzed at the time of enrollment. NOTE: Participants receiving neuromuscular blockers may be enrolled after a ≥ 12-hour washout period.
  • 12. Participant is tracheostomized at the time of enrollment.
  • 13. Participant is on home non-invasive ventilation (except for CPAP or BiPAP for obstructive sleep apnea).
  • 14. Participant is receiving or expected to receive comfort measures (palliative, hospice, comfort care, etc.) at the time of screening or enrollment.
  • 15. Participant is participating in any of the following:
  • A study with the same or similar primary endpoint
  • A study investigating electrical stimulation or respiratory muscle therapy
  • Any study in which the investigator determines may interfere with the results of this study
  • 16. Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.
  • 17. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results.
  • 18. Participant or legally authorized representative is unwilling to provide written informed consent.
  • 19. Participant or legally authorized representative is unable to provide written informed consent.

About Liberate Medical

Liberate Medical is an innovative clinical trial sponsor dedicated to advancing healthcare solutions through cutting-edge research and development. Focused on improving patient outcomes, the company specializes in the design and execution of clinical trials aimed at evaluating novel medical technologies and therapies. With a commitment to ethical practices and regulatory compliance, Liberate Medical collaborates with healthcare providers, researchers, and regulatory bodies to ensure the rigor and integrity of its studies. By leveraging data-driven insights and patient-centered approaches, Liberate Medical strives to bring transformative medical advancements to market, ultimately enhancing the quality of care for patients worldwide.

Locations

Houston, Texas, United States

Iowa City, Iowa, United States

Pittsburgh, Pennsylvania, United States

Cincinnati, Ohio, United States

Houston, Texas, United States

Boston, Massachusetts, United States

Nashville, Tennessee, United States

Cincinnati, Ohio, United States

Maywood, Illinois, United States

Rotterdam, , Netherlands

Hines, Illinois, United States

Nijmegen, , Netherlands

Houston, Texas, United States

Clayton, , Australia

Everett, Washington, United States

Randwick, , Australia

Kogarah, , Australia

St. Leonards, , Australia

Kingswood, , Australia

Houston, Texas, United States

Paris, , France

'S Hertogenbosch, , Netherlands

Nijmegen, , Netherlands

Patients applied

0 patients applied

Trial Officials

Angus Mclachlan, PhD

Study Director

Liberate Medical

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials